Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Phase 3

Completed

• Conditions: Hepatitis A; Hepatitis B; Meningococcal Disease; Meningococcal Meningitis
• Interventions: Biological: MenACWY-CRM; Biological: Combined inactivated hepatitis A & recombinant hepatitis B; Biological: Recombinant hepatitis B vaccine; Biological: Inactivated hepatitis A vaccine

• Registration Number: NCT01453348
• Lead Sponsor: Novartis Vaccines

Brief Summary

This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-10
• Study First Submitted: 2011-10-03
• Study First Submitted QC: 2011-10-12
• Study First Posted: 2011-10-17
• Primary Completion: 2012-01
• Study Completion: 2012-01
• Disposition First Submitted: 2012-11-20
• Disposition First Submitted QC: 2012-11-20
• Disposition First Posted: 2012-11-22
• Results First Submitted: 2013-10-22
• Results First Submitted QC: 2014-02-06
• Results First Posted: 2014-03-10
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-08
• Last Update Posted: 2017-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 252

Inclusion Criteria

Individuals eligible for enrollment in this study were female and male subjects who had shown to be healthy and who were:

1. Between 18 and 64 years of age inclusive and who had given their written informed consent;
2. Available for all visits and telephone calls scheduled for the study;
3. In good health as determined by medical history, physical examination and clinical judgment of the investigator;
4. For female subjects, had a negative urine pregnancy test.

Exclusion Criteria

Individuals not eligible to be enrolled in the study were those:

1. Who were breastfeeding.

2. Who had a previous personal history of Neisseria meningitidis, hepatitis A or hepatitis B infection.

3. Who received previous immunization with any meningococcal vaccine.

4. Who received previous hepatitis A and/or B vaccination, determined by history (interview of the subject) and/or by review of his or her vaccination card, if less than 5 years have elapsed since vaccination.

5. Who received investigational agents or vaccines within 30 days prior to enrollment or who expected to receive an investigational agent or vaccine prior to completion of the study.

6. Who received live licensed vaccines within 30 days and inactive vaccine within 15 days prior to enrollment or for whom receipt of a licensed vaccine was anticipated during the study period (Exception: Influenza vaccine might have been administered up to 15 days prior to each study immunization and no less than 15 days after each study immunization).

7. Who experienced, within the 7 days prior to enrollment, significant acute infection (for example requiring systemic antibiotic treatment or antiviral therapy) or had experienced fever (defined as body temperature ≥ 38°C) within 3 days prior to enrollment.

8. Who had any serious acute, chronic or progressive disease such as:

   • History of cancer
   • Complicated diabetes mellitus
   • Advanced arteriosclerotic disease
   • Autoimmune disease
   • HIV infection or AIDS
   • Blood dyscrasias
   • Congestive heart failure
   • Renal failure
   • Severe malnutrition (Note: Subjects with mild asthma were eligible for enrollment. Subjects with moderate or severe asthma requiring routine use of inhaled or systemic corticosteroids were not eligible for enrollment).

9. Who had epilepsy, any progressive neurological disease or history of Guillain-Barre syndrome.

10. Who had a history of anaphylaxis, serious vaccine reactions, or allergy to any vaccine component, including but not limited to latex allergy and antibiotic allergy.

11. Who had a known or suspected impairment/alteration of immune function, either congenital or acquired or resulting from (for example):

    • Receipt of immunosuppressive therapy within 30 days prior to enrollment (systemic corticosteroids administered for more than 5 days, or in a daily dose > 1 mg/kg/day prednisone or equivalent during any of 30 days prior to enrollment, or cancer chemotherapy);
    • Receipt of immunostimulants;
    • Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 90 days prior to enrollment and for the full length of the study.

12. Who were known to have a bleeding diathesis, or any condition that might have been associated with a prolonged bleeding time.

13. Who had any condition that, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.

14. Who were part of the study personnel or close family members of those conducting this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group 2	Combined inactivated hepatitis A & recombinant hepatitis B	This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
Group 2	Inactivated hepatitis A vaccine	This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
Group 1	Inactivated hepatitis A vaccine	This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' alone on the different visits.
Group 1	Combined inactivated hepatitis A & recombinant hepatitis B	This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' alone on the different visits.
Group 1	Recombinant hepatitis B vaccine	This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' alone on the different visits.
Group 2	MenACWY-CRM	This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
Group 3	MenACWY-CRM	This group will receive only MenACWY-CRM.
Group 2	Recombinant hepatitis B vaccine	This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A \& recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.

Primary Outcome Measures

Name	Time	Method
Geometric Mean antiHAV and antiHBV Concentrations (GMCs), 28 Days After Primary and Booster Vaccination	Day 57 (previously unprimed subjects) day 29 (previously primed subjects) postvaccination.	Assessment was made to demonstrate the non-inferiority of hepatitis A/B vaccine with MenACWY-CRM as compared to hepatitis A/B vaccine without MenACWY-CRM, as measured by geometric mean concentrations on day 57 in previously unvaccinated subjects or on day 29 after a booster dose in previously vaccinated subjects.

Secondary Outcome Measures

Name	Time	Method
Percentages of Subjects With Seroresponse Against N Meningitidis A, C, W and Y Serogroups at Day 29	28 days postvaccination (day 29).	Immunogenicity was assessed as the seroresponse rates for meningococcal serogroups A, C, W and Y elicited by MenACWY-CRM on day 29 when given concomitantly with combined hepatitis A/B vaccine or given alone.; For a subject with a baseline hSBA titer \< 1:4, seroresponse is defined as a postvaccination hSBA titer ≥1:8; for a subject with a baseline hSBA titer ≥ 1:4, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.
hSBA GMTs Assay Titers Against N Meningitidis A, C, W and Y Serogroups at Day 29	28 days post vaccination (day 29).	Immunogenicity was assessed in terms of geometric mean titers (GMTs) of antibodies to meningococcal serogroups A, C, W and Y on day 29 when given concomitantly with combined hepatitis A/B vaccine or given alone.
Percentages of Subjects With Unsolicited Adverse Events (AEs)	Day 1 to day 57.	Safety was assessed in terms of percentage of all spontaneously reported AEs collected from the time the subject signed the informed consent form (day 1), until the subject stopped study participation (day 57).
Percentages of Subjects With antiHAV and antiHBsAg Antibodies Concentrations Above Seroprotection Level 28 Days After Primary or Booster Vaccination	28 days post primary or booster vaccination.	Immunogenicity was assessed as the percentages of subjects with anti-HAV concentration ≥20 mIU/mL and anti- HBsAg antibody concentration ≥10 mIU/mL, 28 days after primary or booster vaccination.

Trial Locations

Locations (4)

04, Novartis Investigational Site; 🇩🇪 Rostock, Germany

03, Novartis Investigational Site; 🇩🇪 Berlin, Germany

02, Novartis Investigational Site; 🇩🇪 Hamburg, Germany

01, Novartis Investigational Site; 🇩🇪 München, Germany